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Altered B-lymphopoiesis in mice 
with deregulated thrombopoietin 
signaling
Amanda E. Au1,2, Marion Lebois1, Starling A. Sim1,2, Ping Cannon1, Jason Corbin1, Pradnya 
Gangatirkar1, Craig D. Hyland1, Diane Moujalled1, Angelika Rutgersson1,3, Fatme Yassinson1,3, 
Benjamin T. Kile  1,2,5, Kylie D. Mason4, Ashley P. Ng1,2, Warren S. Alexander1,2 & Emma C. 
Josefsson  1,2
Thrombopoietin (TPO) is the master cytokine regulator of megakaryopoiesis. In addition to regulation 
of megakaryocyte and platelet number, TPO is important for maintaining proper hematopoietic stem 
cell (HSC) function. It was previously shown that a number of lymphoid genes were upregulated in 
HSCs from Tpo−/− mice. We investigated if absent or enhanced TPO signaling would influence normal 
B-lymphopoiesis. Absent TPO signaling in Mpl−/− mice led to enrichment of a common lymphoid 
progenitor (CLP) signature in multipotential lineage-negative Sca-1+c-Kit+ (LSK) cells and an increase 
in CLP formation. Moreover, Mpl−/− mice exhibited increased numbers of PreB2 and immature 
B-cells in bone marrow and spleen, with an increased proportion of B-lymphoid cells in the G1 phase 
of the cell cycle. Conversely, elevated TPO signaling in TpoTg mice was associated with reduced 
B-lymphopoiesis. Although at steady state, peripheral blood lymphocyte counts were normal in both 
models, Mpl−/− Eµ-myc mice showed an enhanced preneoplastic phase with increased numbers of 
splenic PreB2 and immature B-cells, a reduced quiescent fraction, and augmented blood lymphocyte 
counts. Thus, although Mpl is not expressed on lymphoid cells, TPO signaling may indirectly influence 
B-lymphopoiesis and the preneoplastic state in Myc-driven B-cell lymphomagenesis by lineage priming 
in multipotential progenitor cells.
Platelets are produced from large precursor cells in the bone marrow called megakaryocytes. The process by 
which megakaryocytes produce platelets is unique and involves polyploidisation and shedding of platelets into 
the blood stream1. Thrombopoietin (TPO), produced mainly in the liver, stimulates both megakaryocyte colony 
formation and enhances megakaryocyte maturation in the bone marrow leading to increased platelet production. 
TPO binds to its receptor, TPOR/MPL, which is expressed on hematopoietic stem cells (HSCs), megakaryocytes 
and platelets2. Circulating TPO concentrations are controlled by MPL via receptor-mediated internalization and 
degradation3,4, and in part by sensing of senescent platelets by the Ashwell-Morell receptor in the liver5. Mpl−/− 
mice exhibit platelet counts ~10% of wild-type levels6, while TpoTg transgenic mice, engineered to overexpress 
TPO in the liver, have ~3.5 times higher platelet counts7 compared to wild-type mice. In addition to regulating 
megakaryopoiesis, TPO is known to affect HSC number and quiescence7. A low level of TPO leads to reductions 
in total HSCs, but with more of them in active cycle. This is evident in Mpl deficient mice, which not only exhibit 
thrombocytopenia, but also have increased cycling and a decline in the number of HSCs with age8–10. Conversely, 
a high TPO level leads to a greater proportion of quiescent HSCs7.
It has previously been reported that down-regulation of Mpl marks the transition from pluripotent to 
lymphoid-primed multipotent hematopoietic progenitor cells11 and that a number of lymphoid genes are upreg-
ulated in HSCs from Tpo−/− mice12. Here, we compared the effects of absent or enhanced TPO signaling on 
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steady-state B-lymphopoiesis and in a model of over-active B-lymphopoiesis, the Eµ-myc transgenic mice, which 
display a characteristic preneoplastic phase with expansion of immature Pro- and Pre-B cell populations13,14. We 
found that, although Mpl is not expressed on lymphoid cells, absent TPO signaling in Mpl−/− mice led to lineage 
priming of lineage-negative Sca-1+c-Kit+ (LSK) cells with increased numbers of common lymphoid progeni-
tors (CLPs), PreB2 and immature B-cells. Additionally, Mpl−/− Eµ-myc mice demonstrated an enhanced preneo-
plastic phase that resulted in earlier disease onset. By comparison, elevated TPO signaling modestly suppressed 
B-lymphopoiesis and resulted in delayed disease onset in TpoTg Eµ-myc transgenic mice. Thus, despite the absence 
of Mpl expression in B-lymphoid cells, changes induced in multipotential hematopoietic progenitor cells by 
altered TPO signaling, including altered gene expression and lineage priming, indirectly affect B-lymphopoiesis. 
The effects of altered Mpl signaling at steady-state were confined to changes in B-lymphoid precursor cell num-
bers, with no alteration in circulating B cell number. However, under conditions of excess proliferation modeled 
using Eµ-myc transgenic mice, the changes conferred by altered Mpl signaling in preneoplastic B-lymphopoiesis 
were sufficient to influence the onset of B-cell lymphoma.
Results
Lymphoid lineage skewing in Mpl−/− bone marrow and spleen. In accordance with previous find-
ings reported in adult mice7,15, in the setting of increased TPO signaling, we found that 4–5 week old TpoTg 
mice had a 4-fold increase in numbers of LSK cells and corresponding LSK subpopulations long-term HSCs 
(LTHSCs), short-term HSCs (STHSCs) and lymphoid-primed multipotent progenitors (LMPPs) in the bone mar-
row when compared to wild-type mice (Fig. 1a). While augmented numbers of CLPs and B-cell primed progen-
itors (BLPs), could also be observed in TpoTg bone marrow, this effect was more modest (Fig. 1a, Supplementary 
Fig. S1). In contrast, as previously described7,15, Mpl−/− mice had a significantly reduced number of LSKs (Fig. 1a, 
Supplementary Fig. S1). Interestingly, despite a deficiency in the number of LSKs, numbers of CLPs and BLPs were 
significantly increased in Mpl−/− bone marrow (Fig. 1a, Supplementary Fig. S1). Prior evidence had suggested 
Figure 1. Lymphoid lineage priming in Mpl−/− LSKs. (a) Hematopoietic stem and progenitor cells per femur 
relative to WT in 4–5 weeks old mice. WT (n = 8), Mpl−/− (n = 6) and TpoTg (n = 7). Mean ± SEM. Statistical 
significance was generated by Student’s unpaired t-test. *p < 0.05. (b) Barcode plot of the CLP gene signature in 
Mpl−/− and (c) TpoTg LSKs. Gene set tests were performed using gene set obtained for the CLP population from 
the Hemopedia atlas18.
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that lymphoid-specific gene transcription may be primed early in hematopoiesis16,17. Here, we observed more 
specifically, that relative to wild-type LSKs, a CLP gene expression signature18 was upregulated in Mpl−/− LSKs 
(p = 0.0001) (Fig. 1b, Supplementary Table S1) and conversely down regulated in TpoTg LSKs (p = 0.0001) (Fig. 1c, 
Supplementary Table S1). In confirmation of these results, lineage priming with early B-cell progenitor ProB and 
PreB gene expression signatures was also observed in Mpl−/− LSKs, and that these were conversely downregulated 
in TpoTg LSKs (Supplementary Table S2).
To determine any functional consequences of these altered gene expression profiles, the numbers of lymphoid 
cells were further enumerated in Mpl−/− and TpoTg mice. In 4–5 week old mice, Mpl deficiency led to increased 
PreB2 cell numbers in bone marrow along with elevated immature B-cell numbers in bone marrow and spleen 
(Fig. 2a,b). In contrast, TpoTg mice had reduced numbers of bone marrow ProB-PreB1, PreB2 cells and splenic 
mature B cells (Fig. 2a,b).
While Mpl is expressed on LSK cells, we found the receptor to be absent on CLPs, ProB-PreB1, PreB2, imma-
ture, and mature B cells (Supplementary Fig. S1), excluding an effect via direct TPO signaling in committed 
B-lineage cells. Limiting dilution assays revealed no significant difference in in vitro clonogenicity of purified 
Mpl−/− and TpoTg CLPs relative to wild-type cells (Supplementary Fig. S2). However, in the Mpl−/− spleen, imma-
ture and mature B-cells cycled significantly more than wild-type, as indicated by an increased proportion of 
cells in G1 and a reduced proportion in G0 (Fig. 2d). However, changes in cell cycle status were not evident in 
B-lymphoid cells in TpoTg mice (Fig. 2c,d), nor in Mpl−/− bone marrow (Fig. 2c), and peripheral blood lym-
phocyte counts in Mpl−/− and TpoTg mice were normal (Table 1)15. Thus, although altered TPO signaling may 
Figure 2. Lymphoid lineage priming in Mpl−/− bone marrow and spleen. (a) Bone marrow and (b) spleen 
cellularity of B-cell subsets in 4–5 week old mice. WT (n = 17), Mpl−/− (n = 16) and TpoTg (n = 15). (c-d) Ki-67/
DAPI cell cycling assessment of B-cell subsets within bone marrow and spleen of 4–5 week old WT (n = 17), 
Mpl−/− (n = 17) and TpoTg (n = 13) mice. Statistical significance was generated by Student’s unpaired t-test. 
Mean ± SEM. *p < 0.05; **p < 0.005; ***p < 0.001
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indirectly affect B-lymphopoiesis, other mechanisms were clearly contributing to circulating lymphocyte home-
ostasis at steady state.
TPO restricts Eµ-myc preneoplastic lymphoproliferation. We next investigated the changes in 
B-lymphopoiesis evident in Mpl−/− and TpoTg mice in the context of excess B-lymphoid proliferation in Eµ-myc 
transgenic mice14. We initially confirmed that preneoplastic Eµ-myc B-cell subsets did not express Mpl protein, 
when assessed by flow cytometry (Supplementary Fig. S3) as was the case for wild-type B-cell subsets. The pre-
neoplastic phase in Eµ-myc mice is characterized by a polyclonal expansion of PreB cells accompanied by mild 
splenomegaly19. We observed that relative to 4–5 week-old Eµ-myc control mice, age matched Mpl−/− Eµ-myc 
mice displayed an increase in spleen weight of 1.4-fold (Fig. 3a) which was accompanied by a 1.9-fold increase in 
peripheral blood lymphocyte counts (Fig. 3b). In comparison to Eµ-myc controls, Mpl−/− Eµ-myc mice showed 
a modest reduction in red blood cell number, while, the number of platelets was reduced in the presence of the 
Eµ-myc transgene irrespective of whether mice were on a wild-type or Mpl−/− background (Fig. 3c,d). In order 
to investigate if the observed blood lymphocyte elevation corresponded with changes in B cell precursors in the 
bone marrow and spleen we examined B-cell subsets and cellularity in pre-neoplastic Eµ-myc, Mpl−/− Eµ-myc and 
TpoTg Eµ-myc mice (Fig. 3e,f). We found increased spleen cellularity and a doubling in the number of PreB2 cells 
as well as significant increases in the numbers of immature and mature B-cells in pre-neoplastic Mpl−/− Eµ-myc 
spleen, compared to Eµ-myc mice (Fig. 3f). Moreover, Mpl−/− Eµ-myc mice had increased numbers of immature 
B-cells in the bone marrow (Fig. 3e). Conversely, pre-neoplastic TpoTg Eµ-myc mice had reduced PreB2 cell num-
bers in bone marrow and spleen as well as significantly fewer immature and mature splenic B-cells compared 
to Eµ-myc control mice (Fig. 3e,f). To confirm these results, we next assessed the effect of exogenous TPO on 
the preneoplastic phase by administration of the TPO-mimetic Romiplostim20 in Eµ-myc and littermate control 
animals starting when they were 1 week old. When mice were assessed at 5-weeks of age, platelet counts were 
significantly increased in animals receiving Romiplostim compared to vehicle (Fig. 4a). As expected, 5-week old 
vehicle treated Eµ-myc mice had increased lymphocyte counts, spleen cellularity and bone marrow and spleen 




















































































































Figure 3. Increased lymphoproliferation in preneoplastic Mpl deficient mice. (a) Spleen weight (b) Lymphocyte 
(c) Red blood cell (RBC) and (d) platelet counts in 4–5 week old mice. n = 11–18 mice per genotype. Whiskers: 
Min to Max. (e) Bone marrow and (f) spleen cellularity and Pro-PreB1, PreB2, immature and mature B-cells 
in 4–5 week old mice assessed by flow cytometry. Data are presented as mean ± SEM. n = 11–18 mice per 
genotype. Statistical significance was generated by Student’s unpaired t-test. *p < 0.05; **p < 0.005; ***p < 0.001
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reduced lymphocyte counts, lower spleen cellularity and fewer PreB2 and immature B-cells in both bone marrow 
and spleen when compared to vehicle treated Eµ-myc mice (Fig. 4b,c,d).
Eµ-myc mice have previously been shown to succumb to aggressive lymphoma within 3–6 months after 
birth14. Mpl−/−, TpoTg and wild-type mice aged up to 1 year showed no signs of tumor development during 
the course of the study (Fig. 5a). However, the changes conferred by altered Mpl signaling in preneoplastic 
B-lymphopoiesis were sufficient to influence the onset of B cell lymphoma in Eµ-myc mice. Mpl−/− Eµ-myc mice 
became unwell with a reduced median survival of 76.5 days, compared to conventional Eµ-myc mice (87 days, 
p < 0.0001) (Fig. 5a). Conversely, TpoTg Eµ-myc mice exhibited delayed illness (p = 0.0019) with a median survival 
of 107 days (Fig. 5a). Moribund mice of all three genotypes had splenomegaly (Fig. 5b) and many presented with 
elevated blood lymphocyte counts (Table 1) as well as enlarged lymph nodes (Supplementary Fig. 4b). Spleen 
weights and cellularity were significantly increased in ill Mpl−/− Eµ-myc mice when compared to control Eµ-myc 
mice (Fig. 5b, Supplementary Fig. S4a). The bone marrow revealed diffuse tumor infiltrate of large cells with mul-
tiple nucleoli, as well as frequent extravasation into surrounding tissues (Supplementary Fig. S5). The tumor phe-
notypes, classified as PreB2, immature B-cell or a mixture of the two (mixed), were similarly distributed among 
the genotypes bearing the Eµ-myc transgene (Fig. 5c). Hematocrit and platelet counts often drop in the late stages 
of hematological malignancy including in Eµ-myc induced lymphoma (Table 1). Of note, Mpl−/− Eµ-myc mice 
were substantially more anemic than Eµ-myc and TpoTg Eµ-myc mice (Table 1). At necropsy, lymph node hem-
orrhage was often observed in Mpl−/− Eµ-myc mice, a phenotype not commonly present in the other genotypes 
(Supplementary Fig. S6).
Enhanced cycling of B-lymphoid cells in pre-neoplastic Mpl−/− Eµ-myc mice. Our results support 
a model in which the pre-malignant phase of Eµ-myc lymphomagenesis is affected by the underlying cellular 
changes in mice with altered TPO signaling. Since increased B-lymphoid proliferation in pre-malignant Eµ-myc 
mice is characterized by changes in apoptosis and cell cycling19,21, we examined these processes in the compound 
mutant mice. Bone marrow cells from 4–5 week old Eµ-myc, Mpl−/− Eµ-myc, and TpoTg Eµ-myc mice were cul-
tured for 24 hours under conditions of cytokine deprivation, and apoptosis was measured in B-cell subsets by 
Annexin-V binding. In accord with previous studies21, Eµ-myc B-cell subsets were highly sensitive to apoptosis 
compared to wild-type control cells (Supplementary Fig. S7). However, no differences in B-cell apoptosis were 
observed in Mpl−/− Eµ-myc or TpoTg Eµ-myc cells (Supplementary Fig. S7).
TPO has an established role in the control of HSC number and quiescence6,7, and we confirmed reduced 
quiescence (G0) in Mpl−/− LSKs and conversely increased quiescence in TpoTg LSKs (Supplementary Fig. S8c). 
Eµ-myc LSKs expressed Mpl to the same extent as wild-type cells (Supplementary Fig. S8a) and similar changes in 
LSK cell number and cell cycling were observed in Mpl−/− and TpoTg mice in the presence and absence of Eµ-myc 
(Supplementary Fig. S8b,c). We next investigated if there were differences in cycling of ProB-PreB1, PreB2, imma-
ture and mature B-cells in bone marrow and spleen of preneoplastic Mpl−/− Eµ-myc, TpoTg Eµ-myc, and Eµ-myc 






























































































































































Figure 4. Effects of TPO-mimetic on preneoplastic phase. 1-week-old Eμ-myc mice and their wild-type 
littermates were injected subcutaneously every 3 days with 100 μg/kg Romiplostim or saline vehicle. At 5 weeks 
of age (a) platelet and (b) lymphocyte counts (c) spleen cellularity, PreB2, and immature B-cells, and (d) bone 
marrow cellularity, ProB PreB1, PreB2 and Immature B-cells. n = 8–14 mice per group. Data are presented 
as mean ± SEM. Statistical significance was generated by Student’s unpaired t-test. *p < 0.05; **p < 0.005; 
***p < 0.001. BM = bone marrow.
www.nature.com/scientificreports/
6Scientific REpoRts | 7: 14953  | DOI:10.1038/s41598-017-15023-2
B cells in active cycle compared with controls19. In keeping with these findings we found an increased proportion 
of PreB2, immature and mature B-cells in active cycle in Eµ-myc mice compared to healthy controls (Figs 2 and 
6). Consistent with our findings in Mpl−/− mice, this effect was augmented in Mpl−/− Eµ-myc PreB2-, imma-
ture and mature B-lymphocytes, while a reverse effect was observed in immature and mature B-cells in TpoTg 
Eµ-myc mice, particularly in the spleen (Fig. 6a,b). Thus, the accumulation of B-lymphoid cells in preneoplastic 
Mpl−/− Eµ-myc mice is likely to be the result of further deregulation of the already increased rate of proliferation 



































































Figure 5. TPO delays B-cell lymphoma development in Eµ-myc mice. (a) Survival of Eµ-myc (n = 83), Mpl−/− 
Eµ-myc (n = 200), TpoTg Eµ-myc (n = 58), WT (n = 14), Mpl−/− (n = 11) and TpoTg (n = 13) mice. P-values were 
generated with Logrank (Mantel-Cox) test. (b) Spleen weight in terminally ill mice and 1-year old control mice. 
Eµ-myc (n = 47), Mpl−/− Eµ-myc (n = 59), TpoTg Eµ-myc (n = 56), WT (n = 5), Mpl−/− (n = 7) and TpoTg (n = 6). 
Whiskers: Min to Max. Statistical significance was generated by Student’s unpaired t-test. *p < 0.05; **p < 0.005; 
***p < 0.001. (c) Bone marrow disease phenotype in terminally ill mice assessed by flow cytometry. Eµ-myc 
(n = 31), Mpl−/− Eµ-myc (n = 36) and TpoTg Eµ-myc (n = 25) mice.
WT Mpl−/− TpoTg Eµ-myc Mpl−/− Eµ-myc TpoTg Eµ-myc
n = 14 n = 11 n = 13 n = 58 n = 81 n = 62
Platelets (x 106/ml) 1338 ± 245 172 ± 145*** 4748 ± 745*** 704 ± 283*** 31 ± 16***,^^^ 2227 ± 951***,^^^
MPV (femtoliter) 7.5 ± 1.3 10.9 ± 4.1** 8.4 ± 1.2 7.3 ± 1.4 11.8 ± 3.2***,^^^ 7.3 ± 1.2
Hematocrit (%) 55.0 ± 3.3 49.3 ± 8.9 52.0 ± 3.5 49.2 ± 8.5* 33.6 ± 10.5***,^^^ 47.3 ± 4.6**
RBCs (x109/ml) 10.5 ± 0.7 9.6 ± 1.8 9.8 ± 1.4 9.7 ± 1.7 6.2 ± 2.1***,^^^ 9.8 ± 0.9
Leukocytes (x106/ml) 8.1 ± 3.2 6.9 ± 2.7 10.2 ± 3.5 57.4 ± 77 35.9 ± 36 87.2 ± 101***
Lymphocytes (x106/ml) 6.3 ± 2.4 5.3 ± 2.2 8.2 ± 3.3 27.7 ± 38 23.0 ± 23 49.5 ± 60***,^^
Neutrophils (x106/ml) 1.2 ± 0.4 0.8 ± 0.3 1.6 ± 0.6 5.7 ± 4.2** 3.0 ± 2.6^^^ 9.9 ± 6.0***,^^^
Monocytes (x106/ml) 0.1 ± 0.0 0.1 ± 0.1 0.2 ± 0.1 0.2 ± 0.3 0.2 ± 0.3 0.7 ± 0.5***,^^^
Eosinophils (x106/ml) 0.3 ± 0.4 0.1 ± 0.1 0.2 ± 0.1 0.2 ± 0.2 0.2 ± 0.2 0.4 ± 0.3^^
Table 1. Peripheral blood counts from ~1 year-old mice (WT, Mpl-/- and TpoTg) and terminally ill Eµ-
myc mice. Data represent mean ± SD, 1 way ANOVA with Dunnett’s multiple comparison test. Significance 
compared to wild-type (WT) *p < 0.05; **p < 0.005; ***p < 0.001; significance compared to Eµ-myc 
^^p < 0.005; ^^^p < 0.001. Mean platelet volume (MPV), red blood cell (RBCs).
www.nature.com/scientificreports/
7Scientific REpoRts | 7: 14953  | DOI:10.1038/s41598-017-15023-2
Discussion
Our findings demonstrated that perturbed TPO signaling had a clear effect on the lymphoid compartment at 
steady state using genetically modified Mpl−/− and TpoTg models. The earliest stages of the hematopoietic hier-
archy where this effect was apparent was observed in Mpl expressing LSK cells, where an upregulation of CLP, 
ProB and PreB gene expression signatures in Mpl−/− LSK cells confirmed prior data from Sanjuan-Pla et al. that 
showed an upregulation of lymphoid genes in HSCs from Tpo−/− mice, while Tpo−/− bone marrow cells gave 
lymphoid-biased reconstitution when transplanted12. Together, these data suggest absence of TPO signaling on 
LSK cells results in lineage priming with enhanced early lymphoid gene expression. In support of the biological 
significance of the upregulated CLP, ProB and PreB signatures in Mpl−/− LSKs, we found an increased number of 
CLPs in Mpl−/− bone marrow. Moreover, we demonstrate that 4–5 week old Mpl−/− mice exhibit increased PreB2 
and immature B-cell counts in bone marrow and spleen, with an increased proportion of immature and mature 
splenic B-cells in active cycle. Conversely, elevated TPO signaling in TpoTg mice negatively affected bone marrow 
and spleen B-lymphopoiesis. These effects on committed B-lymphoid precursor cell numbers must be indirect, 
since previous studies, also confirmed here, have shown that while LSK cells express the Mpl receptor, CLP and 
B-cell subsets do not11,15,22–24. The in vitro clonogenicity of CLPs from Mpl−/− and TpoTg mice was unaltered, but 
changes in the cell cycling profiles of B-lymphoid precursor cells correlated with altered cell numbers in these 
mice. Interestingly, the master erythroid cytokine regulator, EPO, has also been shown, in addition to stimulating 
erythropoiesis, to negatively affect B-lymphopoiesis at the ProB-cell and PreB-cell stage of maturation, by an 
indirect mechanism within the bone marrow environment25.
The altered B-lymphopoiesis observed in Mpl−/− and TpoTg bone marrow and spleen was, however, not suffi-
cient to influence lymphocyte counts in the peripheral blood at steady state. Nevertheless, we hypothesized that 
changes to B-lymphopoiesis evident in mice with altered TPO signaling might have more dramatic consequences 
in a perturbed system. Thus, we investigated the preneoplastic phase in Eµ-myc transgenic mice, which is charac-
terized by increased B-lymphoid cell cycling and lymphocytosis. We observed accumulation of PreB2, immature 
and mature B-cells in preneoplastic Mpl−/− Eµ-myc mice relative to that in Eµ-myc controls, an effect that was 
reversed in TpoTg Eµ-myc mice. Furthermore, the effect on preneoplastic Eµ-myc mice was also countered by 4 
weeks of Romiplostim administration, when mice were 1 to 5 weeks of age. While the increased apoptosis char-
acteristic of Eµ-myc B-lymphoid cells21 was unaltered in Mpl−/− Eµ-myc and TpoTg Eµ-myc mice, the increased 
B-lymphoid cell cycling caused by Eµ-myc expression was augmented in Mpl−/− Eµ-myc mice and attenuated in 































































































































































































































Figure 6. Increased B-cell cycling in preneoplastic Mpl−/− Eµ-myc mice. Cell cycle status of (a) bone marrow 
and (b) spleen B-cell subsets in 4–5 week old Eµ-myc (n = 13), Mpl−/− Eµ-myc (n = 22) and TpoTg Eµ-myc 
(n = 13) mice assessed by Ki-67/DAPI staining profiles. Statistical significance was compared to Eµ-myc. 
Statistical significance was generated by Student’s unpaired t-test. Mean ± SEM. *p < 0.05; **p < 0.005; 
***p < 0.001.
www.nature.com/scientificreports/
8Scientific REpoRts | 7: 14953  | DOI:10.1038/s41598-017-15023-2
outcome: illness from B-lymphoma developed with a reduced latency in Mpl−/− Eµ-myc mice and was delayed in 
TpoTg Eµ-myc mice. This result is in agreement with a recent study which reported that Mpl deficiency increased 
precursor B-ALL development in the Lnk−/−Tp53−/− mouse model26.
Our results support a model in which the direct influence of the Eµ-myc transgene and the indirect effect of 
loss of TPO signaling, at least in part due to lymphoid lineage priming in multipotential hematopoietic cells, 
appear to have an additive effect on cell cycling and accumulation of B-lymphoid populations resulting in an 
enhanced preneoplastic state and earlier disease onset in Mpl−/− Eµ-myc mice. The suppressive indirect impact of 
excess TPO signaling in TpoTg mice was also evident in the presence of the Eµ-myc transgene and could account 
for the delayed disease initiation in TpoTg Eµ-myc mice. Lymph node intratumor hemorrhage was occasionally 
observed in terminally ill Mpl−/− Eµ-myc mice, which is consistent with previous recognition of hemorrhaging 
of solid tumors in severely thrombocytopenic mice27,28. Thus, while excess bleeding may have contributed to the 
terminal stage of disease in Mpl−/− Eµ-myc mice, the significant preneoplastic expansion of splenic B lymphoid 
cell numbers (PreB2, immature and mature B-cells) and blood lymphocyte counts support a significant contribu-
tion by altered B-lymphopoiesis.
While no megakaryocyte-associated fibrosis29,30 was observed in 4–5 week old TpoTg mice (data not shown), 
our data cannot exclude an effect on B-lymphopoiesis from altered environmental niches or competition for space 
arising from abnormal megakaryocyte number in the bone marrow and spleen as Mpl−/− mice have 10% of nor-
mal megakaryocyte and platelet numbers, while TpoTg mice have ~3.5-fold increased platelet counts with 3-fold 
elevated bone marrow and spleen megakaryocytes7,15,31 (Supplementary Fig. S5b).
In addition, platelets have been shown to protect tumor vasculature28 and to promote hematogenous metas-
tasis in mouse models32,33. Although limited information is available on roles of platelets in lymphoma and leu-
kemia, some recent studies have examined interactions between lymphoma and leukemia cell lines and activated 
platelets or platelet-released molecules34–36. Although, the present study investigated the preneoplastic phase in 
Eµ-myc mice, future studies are needed to explore potential effects of altered megakaryocyte or platelet numbers 
that may alter the biological behavior of established lymphoma.
Material and Methods
Mice. Eµ-myc14, Mpl−/− 6 and TpoTg 7 mice have been previously described. All mutations were backcrossed 
onto the C57BL/6 background for at least 10 generations prior to this study. Experiments include balanced groups 
of male and female mice if not otherwise stated. Eµ-myc mice included in the survival study were taken at an 
ethical endpoint when displaying lymphadenopathy and/or splenomegaly. All animal experiments complied with 
the regulatory standards of, and were approved by the Walter and Eliza Hall Institute (WEHI) Animal Ethics 
Committee.
Peripheral blood counts. Automated cell counts were performed on blood collected from the retro-orbital 
plexus or by cardiac puncture into Microtainer tubes containing EDTA (Sarstedt, Ingle Farm, SA Australia), using 
an Advia 2120 hematological analyser (Siemens, Munich Germany).
Progenitor and B-cell subset analysis. 4–5 week old, 1–year old or terminally ill mice were analyzed. 
Organ processing: Bone marrow was flushed from femurs and tibias in 10 mL of balanced salt solution (BSS; 
150 mM NaCl, 3.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 7.4 mM HEPES.NaOH, 1.2 mM KH2PO4, 0.8 mM 
K2HPO4, pH 7.2) supplemented with 2% fetal calf serum (FCS) and gently pipetted to create a single-cell suspen-
sion. Cell suspensions were centrifuged at 1500 g, 5 min at 4 °C. Supernatant was then aspirated and the pellet was 
resuspended in 3 ml of BSS 2% FCS. Cells were filtered using a 100 μm cell strainer. Spleen cell suspensions were 
prepared by physical dissociation in 3 ml of BSS 2% FCS. Subsequently, 7 ml of Red Cell Removal Buffer (156 mM 
NH4Cl, 0.1 mM EDTA, and 12 mM NaHCO3) was added for 1 min at room temperature. After centrifugation the 
supernatants were aspirated and the pellet was resuspended in 5 ml of BSS 2% FCS. Cell suspensions were filtered 
using a 100 μm cell strainer. B-cell populations were defined as ProB-PreB1 (B220+ cKit+), PreB2 (B220+ cKit− 
IgD– IgM−), Immature (B220+ cKit− IgD− IgM+), Mature (B220+ cKit− IgD+ IgM+). LSK (Lin− Sca1+cKit+), 
LTHSC (Lin− Sca-1+ cKit+ CD34low/−), STHSC (Lin− Sca-1+ cKit+ CD34+ FLT3−), LMPP (Lin− Sca-1+ CD34+ 
FLT3+), CLP (Lin− Sca-1int cKitint IL7R+ FLT3+), ALP (Lin− Sca-1int cKitint IL7R+ FLT3+ Ly6D−), BLP (Lin− Sca-
1int cKitint IL7R+ FLT3+ Ly6D+). Data was acquired using a LSRFortessa flow cytometer (BD, Franklin Lakes, NY, 
USA), and data analysis was performed using FlowJo software 10.3.0 (Treestar Inc, Ashland, USA).
LSK gene expression analysis. Gene set tests were performed on microarray data generated from 
sorted LSK cells from adult wild-type C57BL/6, Mpl−/− and TpoTg mice. Total RNA was hybridized to Illumina 
MouseWG-6v2 bead chip arrays15. The microarray data are available at Array express (www.ebi.ac.uk/arrayex-
press) under accession no. E-MTAB-2389. Results were normalized using the neqc(x) function in limma and gene 
expression was fitted to the linear model using empiric Bayes and array weights. Gene set tests were performed 
using gene sets obtained for the CLP, ProB and PreB populations from the Hemopedia atlas (haemosphere.org)18 
using the top 77 upregulated genes for each population compared to the highest gene expression across the entire 
dataset. Using the Roast function in Limma, a self-contained rotational gene set testing method37, gene set enrich-
ment was tested in Mpl−/− and TpoTg LSKs when compared to wild-type and leading-edge genes contributing to 
the enriched CLP expression signature in Mpl−/− LSK cells, as well as downregulated CLP expression signature in 
TpoTg LSK cells, were extracted (Supplementary Table S1).
Analysis of B-lymphoid cell cycling. Single-cell suspensions from bone marrow and spleen of 4–5 week 
old mice were harvested as described above. Nucleated cell count was performed using trypan blue exclusion 
and 20 × 106 cells were stained with antibodies to B220 (clone RA3-6B2; BD Pharmingen Franklin Lakes NY 
USA), CD19 (clone 1D3; ebiosciences San Diego CA USA), c-Kit (clone ACK4; WEHI mAb Facility, Parkville 
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VIC Australia), IgD (clone 11–26 c.2a; Biolegend San Diego CA USA), and IgM (clone 5.1; WEHI mAb Facility) 
for 30 min on ice. Cells were then washed with BSS 2% FCS and stained with the appropriate secondary 
streptavidin-conjugated fluorochromes for another 30 min on ice. Subsequently, cells were fixed and permeabi-
lized with Cytofix/Cytoperm (BD) according to the manufacturer’s instruction for 30 min on ice. Cells were then 
incubated with either FITC-conjugated anti-Ki-67 antibody or the appropriate FITC-conjugated isotype control 
(BD) overnight at 4 °C. Lastly, 4′,6-diamidino-2-phenylindole (DAPI) (10 μg/ml) (Sigma-Aldrich, St. Louis, MO, 
USA) was added for 30 min at room temperature for analysis of DNA content. Cells were subsequently washed 
and resuspended with BSS 2% FCS and filtered using 40 μm cell strainer prior to analysis. Data was acquired 
using a LSR II flow cytometer (BD), and data analysis was performed using FlowJo software. Here, B-cell subsets 
were defined as: ProB-PreB1 (B220+ cKit+), PreB2 (B220+ CD19+ IgD– IgM−), Immature (B220+ CD19+ IgD− 
IgM+) and Mature (B220+ CD19+ IgD+ IgM+).
Romiplostim. At 6–8 days old, Eμ-myc mice and their wild-type littermates were injected subcutaneously 
with 100 μg/kg Romiplostim38 (Nplate®, Amgen, Thousand Oaks, CA, USA) or saline vehicle. Injections were 
repeated every 3 days until mice were 5-weeks old.
Statistics. Statistical significance between two treatment groups was analyzed using an unpaired Student’s 
t test with two-tailed p-values. One-way ANOVA with multiple comparison test was applied where appropriate 
(GraphPad Prism Version 7). *p < 0.05; **p < 0.005; ***p < 0.001 or as otherwise stated. Data are presented as 
mean ± SD or SEM, indicated in figure legends.
Data availability statement. Figure 1 and Tables S1 and S2 have an associated data source. The microarray 
data are available at Array express (www.ebi.ac.uk/arrayexpress) under accession no. E-MTAB-2389.
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